Acute Myelogeneous Leukemia (AML) in CR1 that is NOT considered as favorable-risk. Favorable risk is defined as having one of the following: t(8.21) without CKIT mutation, inv(16) without CKIT mutation or t(16;16), normal karyotype with mutated NPM1 and not FLT-ITD, normal karyotype with double mutated CEBPA, Acute promyelocytic leukemia (APL) in first molecular remission at end of consolidation
Acute myeloid leukemia (AML): second or greater complete remission (CR); first CR (CR1) in patients >= 60 years old; CR1 in < 60 years old that is NOT considered as favorable risk\r\n* Favorable risk AML is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation\r\n* Normal karyotype with mutated NPM1 but FLT3-ITD wild type\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation
Acute myeloid leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in =< 60 years old that is NOT considered as favorable-risk; favorable risk AML is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation \r\n* Normal karyotype with mutated NPM1 and wild type FLT-ITD\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation
Has favorable risk AML as defined by the presence of isolated t(8;21) or inv(16) or t(16;16)(p13.1;q22) on a standard karyotype or mutated NPM1 with concurrent wild-type FLT3 on molecular testing
Acute myeloid leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in =< 60 years old that is NOT considered as favorable-risk; favorable risk AML is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation\r\n* Normal karyotype with mutated NPM1 and wild type FLT-ITD\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation
Acute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk; favorable risk is defined as having one of the following:\r\n* t(8,21) without CKIT mutation\r\n* inv(16) without CKIT mutation or t(16;16)\r\n* Normal karyotype with mutated nucleophosmin (NPM)1 and not fms-related tyrosine kinase (FLT)-IND\r\n* Normal karyotype with double mutated CCAAT enhancer binding protein alpha (CEBPA)\r\n* Acute promyelocytic leukemia (APL) in first molecular remission at end of consolidation
Acute myelogenous leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in =< 60 years old that is NOT considered as favorable-risk; favorable risk is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation\r\n* Normal karyotype with mutated NPM1 and wild type FLT-ITD\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at end of consolidation
